TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 45.5% in November

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 31,800 shares, a decline of 45.5% from the October 31st total of 58,400 shares. Based on an average daily volume of 44,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.7% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

TLSI has been the topic of several research analyst reports. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm initiated coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Canaccord Genuity Group decreased their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI traded up $0.31 during trading hours on Friday, reaching $4.56. 12,179 shares of the company traded hands, compared to its average volume of 39,311. The firm’s 50-day moving average is $4.23 and its 200-day moving average is $5.43. The stock has a market cap of $139.05 million, a P/E ratio of -1.83 and a beta of 0.49. TriSalus Life Sciences has a 1-year low of $3.61 and a 1-year high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In other news, CEO Mary T. Szela purchased 7,520 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $5.20 per share, with a total value of $39,104.00. Following the purchase, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have acquired 19,560 shares of company stock valued at $95,190. 32.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently bought and sold shares of the stock. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter worth $240,000. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter worth $1,184,000. Duquesne Family Office LLC boosted its holdings in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $66,000. Finally, MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.